Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Ebos Group's average EPS without NRI Growth Rate was -9.90% per year.
During the past 3 years, the average EPS without NRI Growth Rate was -3.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 3.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 6.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ebos Group was 25.20% per year. The lowest was -26.70% per year. And the median was 8.35% per year.
Ebos Group (OTCPK:EBOSF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ebos Group 3-Year EPS without NRI Growth Rate Related Terms
EBOSF vs MCK, COR, CAH: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Distribution subindustry, Ebos Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group 3-Year EPS without NRI Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ebos Group's 3-Year EPS without NRI Growth Rate falls into.
Ebos Group 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -3.80% mean?
Ebos Group (EBOSF) has a 3-Year EPS without NRI Growth Rate of -3.80% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #63 out of 103 companies in the Medical Distribution industry, placing it in the top 61.2%.
Is Ebos Group's 3-Year EPS without NRI Growth Rate too high?
Ebos Group's current 3-Year EPS without NRI Growth Rate is -3.80%. Based on the distribution chart, Ebos Group ranks #63 out of 103 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's 3-Year EPS without NRI Growth Rate compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #63 out of 103 companies for 3-Year EPS without NRI Growth Rate. This places Ebos Group in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Distribution company?
The median 3-Year EPS without NRI Growth Rate among Medical Distribution companies is 2.30, based on 103 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ebos Group and its competitors. For the Medical Distribution industry, the median 3-Year EPS without NRI Growth Rate is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current 3-Year EPS without NRI Growth Rate is -3.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current 3-Year EPS without NRI Growth Rate of -3.80%. The stock's GF Value™ is $43.41, compared to a current price of $23.75 — trading 45.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -3.80%. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ebos Group (EBOSF), the current 3-Year EPS without NRI Growth Rate is -3.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 45.3% below its estimated GF Value™ of $43.41.
Key valuation signals for EBOSF:
3-Year EPS without NRI Growth Rate: -3.80%
GF Value™: $43.41 vs. price of $23.75 (45.3% below fair value)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
